Welcome to our dedicated page for Armata Pharmctcl SEC filings (Ticker: ARMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Armata Pharmaceuticals, Inc. (ARMP) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a clinical-stage biotechnology issuer listed on the NYSE American. Armata files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-37544, including Form 10-K annual reports, Form 10-Q quarterly reports, and Form 8-K current reports describing material events in its bacteriophage therapeutic programs and corporate activities.
Through these filings, investors can review how Armata reports the progress of its AP-SA02 and AP-PA02 programs, including clinical milestones, regulatory interactions, and funding arrangements. Recent Form 8-K filings have covered topics such as positive Phase 2a diSArm data for AP-SA02 in complicated Staphylococcus aureus bacteremia, an End-of-Phase 2 written response from the U.S. Food and Drug Administration supporting advancement to a Phase 3 study, the formal commissioning of the company’s cGMP phage manufacturing facility in Los Angeles, and secured credit agreements with Innoviva Strategic Opportunities LLC.
Filings also detail capital structure and financing tools, including a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC that establishes an at-the-market equity offering program, and secured term loans that are guaranteed by domestic subsidiaries and secured by substantially all of the company’s and certain subsidiaries’ assets. These documents outline key terms, covenants, and potential events of default, giving readers insight into Armata’s financial obligations and liquidity planning.
On Stock Titan, each Armata filing is supplemented with AI-powered summaries that highlight the most important points, helping users quickly understand complex agreements, clinical disclosures, and regulatory language. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, and 10-Ks appear promptly, while access to exhibits allows deeper review of credit agreements, sales agreements, and scientific presentations referenced in the filings. For those tracking ARMP, this page offers a focused view of the company’s official regulatory record, including risk disclosures, operating results, and material corporate developments.
Armata Pharmaceuticals reported that it has received an End-of-Phase 2 written response from the U.S. Food and Drug Administration and plans to advance its intravenously administered Staphylococcus aureus bacteriophage product candidate, AP-SA02, into a Phase 3 clinical study. The planned trial will focus on patients with complicated S. aureus bacteremia, a serious bloodstream infection.
The company disclosed this update through a press release furnished as an exhibit, emphasizing that the information is being provided for informational purposes and is not deemed filed under securities laws. No financial results or transaction details are included in this report.
Armata Pharmaceuticals, Inc. entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC to set up an at-the-market stock offering program. Under this arrangement, Armata may, at its discretion, offer and sell shares of its common stock with an aggregate offering price of up to $100,000,000 through JonesTrading as sales agent. Sales can be made on the NYSE American or other permitted markets and in negotiated transactions, with Armata paying JonesTrading a commission of up to 3.0% of gross sale proceeds and reimbursing certain legal expenses. Neither party is obligated to sell or purchase shares, and the program is limited by the amount registered on Armata’s existing Form S-3 shelf registration and the number of authorized but unissued shares.
Armata Pharmaceuticals is launching an at-the-market offering of up to $100,000,000 of common stock through JonesTrading under a Capital on Demand Sales Agreement. JonesTrading will act as sales agent or principal and receive up to 3.0% commission on gross proceeds.
Based on a recent NYSE American price of $7.10 per share, the company illustrates issuance of about 14.1 million shares, which would raise $100.0 million and increase shares outstanding from 36,406,905 to up to 50,491,412. Armata plans to use net proceeds for working capital and general corporate purposes.
The company highlights substantial doubt about its ability to continue as a going concern and a need for significant additional financing, so this program adds flexible access to equity but could cause immediate and substantial dilution. Innoviva, Inc. beneficially owns more than 50% of the common stock, making Armata a controlled company.
Armata Pharmaceuticals (ARMP) filed its Q3 2025 10-Q reporting a net loss of
Cash and cash equivalents were
Financing activity included a
Armata Pharmaceuticals furnished an update on its bacteriophage program. The company announced positive results from its recently completed Phase 2a diSArm study of AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia, presented at IDWeek 2025.
The company furnished a press release as Exhibit 99.1 and posted the late‑breaking oral presentation delivered by Dr. Loren G. Miller on October 22, 2025, furnished as Exhibit 99.2. The materials were provided under Item 7.01 and are not deemed filed under the Exchange Act nor incorporated by reference into Securities Act filings.
Armata Pharmaceuticals filed a Form S-8 to register an additional 1,811,295 shares of common stock for issuance under its 2016 Equity Incentive Plan and 2016 Employee Stock Purchase Plan. The shares break down into 1,809,153 shares added under the Equity Incentive Plan and 2,142 shares under the ESPP pursuant to annual "evergreen" provisions that operate from January 1, 2017 through January 1, 2026. The filing incorporates prior S-8 registration statements and recent SEC filings, including the Annual Report for the year ended December 31, 2024 and quarterly reports for March 31, 2025 and June 30, 2025. The Registration Statement was signed on August 13, 2025 by Chief Executive Officer Deborah L. Birx.
Armata Pharmaceuticals (ARMP) registered a shelf to sell up to $100,000,000 of securities. Armata is a clinical-stage developer of high-purity, pathogen-specific bacteriophage therapeutics and has completed three Phase 2 trials. AP-PA02 (Pseudomonas) showed favorable safety and sputum P. aeruginosa reductions: the Phase 2 Tailwind post-hoc intent-to-treat analysis (n=33 active, n=15 placebo) showed a CFU reduction at day 17 (P=0.05) and a sustained reduction at day 24 (P=0.015); paired baseline-to-day analyses were significant at multiple timepoints. AP-SA02 (S. aureus) diSArm Phase 1b/2a (n=50) reported investigator-assessed responder rates of 88% vs 58% placebo at TOC (p=0.047) and 100% clinical response at later endpoints (p<=0.017); CEAC analyses supported these findings. Armata has received a $5.0 million CFF award and cumulative DoD/MTEC funding totaling $26.2 million (term extended to March 31, 2026). The prospectus discloses substantial doubt about the company’s ability to continue as a going concern and a need for substantial additional financing; public float was approximately $26.1 million based on 11,077,705 non-affiliate shares at $2.36 per share.
Innoviva and its wholly owned affiliate report that, following transactions described in this Amendment No. 13 to Schedule 13D, the Reporting Persons collectively hold beneficial ownership of 55,467,459 shares of Armata Pharmaceuticals, Inc., representing approximately 83.3% of the issuer's common stock on a fully counted basis. The filing discloses that Innoviva Strategic Opportunities LLC acquired secured debt of the company under an August 11, 2025 credit agreement that provided Armata with a $15,000,000 term loan.
The August 2025 Credit Agreement carries a 14.00% per annum interest rate and matures on January 11, 2029, and is expressly non-convertible. The Reporting Persons continue to hold existing common shares, warrants to acquire 10,653,847 additional shares, and rights to acquire 19,736,843 shares upon conversion of a convertible loan (excluding accrued interest). Except as amended here, prior Schedule 13D disclosures remain in effect.
Armata Pharmaceuticals, Inc. reported a widening operating and net loss in the first half of 2025 as it advances bacteriophage therapeutics. Total assets were $80.8 million versus $86.4 million at year-end 2024, with cash and cash equivalents of $4.3 million and restricted cash of $5.4 million, for combined cash of $9.7 million. The company recorded a six-month net loss of $22.8 million and used $14.8 million of cash in operating activities during the same period.
The balance sheet shows total liabilities of $150.3 million and a stockholders' deficit of $69.5 million, driven by increased current liabilities including a fair-value accounted Convertible Loan of $33.4 million and current term debt of $78.9 million. Management discloses substantial doubt about going concern, stating current cash is insufficient for the next 12 months. Material subsequent financing includes an August 11, 2025 $15.0 million loan from Innoviva at 14% interest; the company also continues to receive MTEC award funding now totaling $26.2 million (term extended to March 31, 2026) to support AP-SA02 development.
FAQ
What is the current stock price of Armata Pharmctcl (ARMP)?
What is the market cap of Armata Pharmctcl (ARMP)?
